Skip to main content
Top
Published in: Urolithiasis 2/2007

01-04-2007 | Original Paper

Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function

Authors: Markus Jaggi, Yasushi Nakagawa, Ljerka Zipperle, Bernhard Hess

Published in: Urolithiasis | Issue 2/2007

Login to get access

Abstract

Tamm-Horsfall protein (THP) powerfully inhibits calcium oxalate crystal aggregation, but structurally abnormal THPs from recurrent calcium stone formers may promote crystal aggregation. Therefore, increased urinary excretion of abnormal THP might be of relevance in nephrolithiasis. We studied 44 recurrent idiopathic calcium stone formers with a positive family history of stone disease (RCSFfam) and 34 age- and sex-matched healthy controls (C). Twenty-four-hour urinary THP excretion was measured by enzyme linked immunosorbent assay. Structural properties of individually purified THPs were obtained from analysis of elution patterns from a Sepharose 4B column. Sialic acid (SA) contents of native whole 24-h urines, crude salt precipitates of native urines and individually purified THPs were measured. THP function was studied by measuring inhibition of CaOx crystal aggregation in vitro (pH 5.7, 200 mM sodium chloride). Twenty-four-hour urine excretion of THP was higher in RCSFfam (44.0 ± 4.0 mg/day) than in C (30.9 ± 2.2 mg/day, P = 0.015). Upon salt precipitation and lyophilization, elution from a Sepharose 4B column revealed one major peak (peak A, cross-reacting with polyclonal anti-THP antibody) and a second minor peak (peak B, not cross-reacting). THPs from RCSFfam eluted later than those from C (P = 0.021), and maximum width of THP peaks was higher in RCSFfam than in C (P = 0.024). SA content was higher in specimens from RCSFfam than from C, in native 24-h urines (207.5 ± 20.4 mg vs. 135.2 ± 16.1 mg, P = 0.013) as well as in crude salt precipitates of 24-h urines (10.4 ± 0.5 mg vs. 7.4 ± 0.9 mg, P = 0.002) and in purified THPs (75.3 ± 9.3 μg/mg vs. 48.8 ± 9.8 μg/mg THP, P = 0.043). Finally, inhibition of calcium oxalate monohydrate crystal aggregation by 40 mg/L of THP was lower in RCSFfam (6.1 ± 5.5%, range −62.0 to +84.2%) than in C (24.9 ± 6.0%, range −39.8 to +82.7%), P = 0.022, and only 25 out of 44 (57%) THPs from RCSFfam were inhibitory (positive inhibition value) vs. 25 out of 34 (74%) THPs from C, P < 0.05. In conclusion, severely recurrent calcium stone formers with a positive family history excrete more THP than healthy controls, and their THP molecules elute later from an analytical column and contain more SA. Such increasingly aggregated THP molecules predispose to exaggerated calcium oxalate crystal aggregation, an important prerequisite for urinary stone formation.
Literature
1.
go back to reference Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401PubMed Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401PubMed
2.
go back to reference Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676CrossRef Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676CrossRef
3.
go back to reference Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMedCrossRef Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMedCrossRef
4.
go back to reference Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMedCrossRef Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMedCrossRef
5.
go back to reference Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 19:2192–2197PubMedCrossRef Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 19:2192–2197PubMedCrossRef
6.
go back to reference Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef
7.
go back to reference Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management, Chap. 1. Lippincott-Raven Publishers, Philadelphia Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management, Chap. 1. Lippincott-Raven Publishers, Philadelphia
8.
go back to reference Fleisch H (1987) Inhibitors and promoters of stone formation. Kidney Int 13:361–371 Fleisch H (1987) Inhibitors and promoters of stone formation. Kidney Int 13:361–371
9.
go back to reference Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854PubMed Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854PubMed
10.
go back to reference Khan SR (1997) Tubular surface events during nephrolithiasis. Curr Opin Urol 7:240–247CrossRef Khan SR (1997) Tubular surface events during nephrolithiasis. Curr Opin Urol 7:240–247CrossRef
11.
go back to reference Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136:128–131PubMed Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136:128–131PubMed
12.
go back to reference Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMed Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMed
13.
go back to reference Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMed Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMed
14.
go back to reference Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMed
15.
go back to reference Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMed Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMed
16.
go back to reference Knörle R, Schnierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. Clin Chem 40:1739–1743PubMed Knörle R, Schnierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. Clin Chem 40:1739–1743PubMed
17.
go back to reference Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 14:1580–1587CrossRef Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 14:1580–1587CrossRef
18.
go back to reference Reinhart HH, Obedeanu N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. Am J Pathol 92:199–205 Reinhart HH, Obedeanu N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. Am J Pathol 92:199–205
19.
go back to reference Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. Biochem J 120:417–424PubMed Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. Biochem J 120:417–424PubMed
20.
go back to reference Aminoff D (1961) Method for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81:384–392PubMed Aminoff D (1961) Method for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81:384–392PubMed
21.
go back to reference Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. Br J Urol 47:733–738CrossRef Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. Br J Urol 47:733–738CrossRef
22.
go back to reference Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRef Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRef
23.
go back to reference Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 68:529–535PubMed Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 68:529–535PubMed
24.
go back to reference Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. Am J Kidney Dis 24:893–900PubMed Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. Am J Kidney Dis 24:893–900PubMed
25.
go back to reference Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMedCrossRef Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMedCrossRef
26.
go back to reference Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53:492–495PubMedCrossRef Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53:492–495PubMedCrossRef
27.
go back to reference Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int 62:87–92PubMedCrossRef Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int 62:87–92PubMedCrossRef
28.
go back to reference Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. Nephrol Dial Transplant 20:1407–1415PubMedCrossRef Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. Nephrol Dial Transplant 20:1407–1415PubMedCrossRef
29.
go back to reference Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55–e60PubMedCrossRef Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55–e60PubMedCrossRef
Metadata
Title
Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function
Authors
Markus Jaggi
Yasushi Nakagawa
Ljerka Zipperle
Bernhard Hess
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Urolithiasis / Issue 2/2007
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-007-0083-7

Other articles of this Issue 2/2007

Urolithiasis 2/2007 Go to the issue